Can Sleep Rhythms Buffer a Wake Chemical in Alzheimer's?
In Alzheimer's disease, higher levels of the wake chemical orexin went with faster decline over three years, unless deep sleep still had strong rhythms.
In one paragraph
Orexin is a brain chemical that keeps us awake. In this study of 60 people with mild-to-moderate Alzheimer's disease, higher orexin in spinal fluid was linked to worse thinking, more behavioural symptoms and more tau over 36 months. People with more sleep spindles and longer slow oscillations had lower orexin, and these deep-sleep rhythms softened the link between orexin and decline. The study is observational, with no healthy comparison group, so it cannot show cause.
How did researchers study orexin and sleep in Alzheimer's?
At a memory clinic in Lleida, Spain, 60 people aged 60 or over with biomarker-confirmed mild-to-moderate Alzheimer's disease took part. Thirty were women, and the mean age was 74.7.
Each had one full night of sleep recording with 34 EEG channels. The next morning, spinal fluid was tested for orexin-A, amyloid-β42, tau and the inflammation marker YKL-40. Algorithms, checked by two investigators, counted sleep spindles and slow oscillations, two rhythms of deep non-REM sleep linked to memory.
Memory, thinking and behavioural symptoms were assessed at baseline and over 36 months. The analysis adjusted for age, sex, amyloid and sleep apnoea, and tested whether sleep rhythms changed the link between orexin and outcomes.
What did the study find about orexin, sleep and decline?
Higher orexin was linked to worse thinking and memory scores and more severe behavioural symptoms over 36 months. It was also linked to higher tau, phosphorylated tau and YKL-40.
More spindles and longer slow oscillations went with lower orexin, while total sleep time and sleep efficiency did not. In people with stronger spindle and slow oscillation activity, the links between orexin and decline were weaker, even after accounting for amyloid and tau.
Women had higher orexin than men (837 vs 673 pg/mL). Results were materially unchanged after adjusting for the severity of sleep apnoea or for YKL-40.
Why does the orexin and sleep link matter in Alzheimer's?
Sleep problems affect up to two-thirds of people with Alzheimer's disease, and drugs that block orexin are already approved for insomnia and being explored in dementia. Understanding how orexin and deep-sleep rhythms relate to decline could guide such trials.
The authors urge caution: if high orexin is partly a compensatory response, suppressing it too strongly could have unintended consequences. They suggest trials track spindle and slow oscillation measures to confirm a drug works as intended without worsening sleep.
A fair reading is that deep-sleep rhythms may be a marker of resilience worth testing in trials. This study doesn't change practice on its own and is not medical advice.
What are the limits of this orexin and Alzheimer's study?
Read before you quote it
The study has important limits:
- Observational design. It shows associations, not cause.
- No healthy comparison group. The findings may reflect ageing rather than Alzheimer's specifically.
- One night of sleep. Sleep was recorded once, with no adaptation night.
- Sleep apnoea. About 70% had moderate-to-severe apnoea, which can change sleep rhythms.
- Modest size. Sixty participants, although such combined data are rare.
The study does not show that orexin-blocking drugs or any sleep treatment slow Alzheimer's disease. It also does not show whether high orexin drives the disease or is a response to it, or whether the same patterns appear in healthy ageing.
- It does not show that orexin-blocking sleep drugs or sleep training slow Alzheimer's disease.
- It does not show whether high orexin drives the disease or is a response to it.
- It was observational, so it cannot show that orexin or sleep rhythms cause decline or protection.
- There was no cognitively healthy comparison group, so the findings may not be specific to Alzheimer's disease.
- Sleep was recorded for a single night, without an adaptation night.
- About 70% of participants had moderate-to-severe sleep apnoea, which can itself change sleep rhythms.
Takeaways
- saysIn people with Alzheimer's, higher orexin in spinal fluid went with worse thinking, more behavioural symptoms, and more tau over three years.
- saysStronger deep-sleep rhythms, spindles and slow waves, went with lower orexin and softened its link with decline.
- saysIt's an observational study with no healthy comparison group, so it can't show cause.
- explainsSleep spindles and slow oscillations are rhythms of deep non-REM sleep that support memory and the stability of brain networks.
- interpretsA fair reading is that deep-sleep rhythms could be a measure of resilience worth tracking in Alzheimer's trials.
Ask the paper
In PaperSays you can ask this paper anything, by text or by saying “Hey Aiden”. Three questions listeners asked:
What is orexin and how is it linked to Alzheimer's?
Orexin keeps the brain awake; in this study, higher spinal fluid orexin went with faster decline in people with Alzheimer's. Hear the full answer in the app →
Can deep sleep protect against Alzheimer's decline?
Stronger deep-sleep rhythms softened the orexin-decline link here, but the study cannot show protection. Ask in the app →
Do orexin-blocking sleep drugs help Alzheimer's?
This study did not test them, and the authors urge careful trials because suppressing orexin could backfire. Ask in the app →
Briefing reviewed by an editor before publication. The paper belongs to its authors; this page summarises it and links to the original. Paper licence: CC BY 4.0. Corrections: support@papersays.com.